What changed from existing technology?
This study compares the outcomes of surgery and radiation therapy after chemotherapy and immunotherapy for advanced esophageal cancer, aiming to find the best treatment option.
This is the first study to compare the long-term outcomes of curative surgery and radical radiotherapy following neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 3
py with ICIs for esophageal squamous cell carcinoma: a real world study. The individualized local treatment selection after neoadjuvant chemoimmunotherapy remai
Title ↗ve cohort study was conducted on locally advanced ESCC patients treated at the People’s Hospital of Guangxi Zhuang Autonomous Region from June 2020 to Decembe
Abstract ↗atment selection after neoadjuvant chemoimmunotherapy remains an unresolved clinical issue and requires validated risk-stratification tools, such as the
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This study may help clinicians choose between surgery and radiation therapy for patients with locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.